Alisertib Plus Paclitaxel in Patients With Advanced Breast Cancer or Recurrent Ovarian Cancer

Leggi l'articolo originale


This phase 1 and 2 clinical trial examines progression-free survival in patients with ovarian or breast cancer treated with alisertib in combination with paclitaxel vs paclitaxel alone.

Lascia un commento